Adagio Medical Holdings (ADGM) AI Stock Analysis

• Market Cap: $16.00M
• Dividend Yield: N/A
• Average Volume (3M): 672.60K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.33
• Revenue Growth: 15.00%
• EPS Growth: 71.57%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.35
• Shares Outstanding: 15,381,565
• 10 Day Avg. Volume: 343,379
• 30 Day Avg. Volume: 672,597
• PEG Ratio: 0.01
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 59.32
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: 1.85
• Enterprise Value/Revenue: 704.17
• Enterprise Value/Gross Profit: -20.78
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: $1.00 ▲(16.28% Upside)

Adagio Medical Holdings is currently facing significant financial and operational challenges. The company's financial performance is weak, with consistent losses and negative cash flows. Technical analysis indicates a bearish trend, and valuation metrics are unattractive due to negative profitability. These factors collectively result in a low overall stock score.

Adagio Medical Holdings Business Overview & Revenue Model

Company Description

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.

How the Company Makes Money

Adagio Medical Holdings generates revenue through multiple streams, primarily by selling its proprietary medical devices and therapies to hospitals, healthcare institutions, and clinics. The company employs a direct sales force as well as strategic partnerships with distributors to reach a broader market. Additionally, ADGM may also engage in licensing agreements for its technologies, allowing other companies to manufacture or distribute its products in exchange for royalties. Key revenue drivers include successful product launches, ongoing sales of existing devices, and potential partnerships with larger medical firms that can amplify distribution and market penetration. The company's focus on innovation and addressing specific medical needs further contributes to its potential earnings growth.

Adagio Medical Holdings Financial Statement Overview

Summary

Adagio Medical Holdings is facing significant financial challenges, with consistent losses and negative cash flows. Despite slight improvements in equity and cash position, the company remains highly leveraged and struggles with profitability. The medical devices industry is competitive, and the company needs to address operational inefficiencies and improve revenue generation to achieve financial stability.

Income Statement

Adagio Medical Holdings has experienced declining revenues over the past years, with a negative revenue growth rate from 2023 to 2024. The company has consistently reported negative gross profit and net income, indicating significant challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage, although it has improved from 2023 to 2024 as equity turned positive. The equity ratio remains low, suggesting limited financial stability. Despite improvements in stockholders' equity, the company still faces potential risks due to its high liabilities relative to assets.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, which have slightly improved from 2023 to 2024. The company has relied on financing activities to support its cash position, which may not be sustainable in the long term. The operating cash flow to net income ratio is negative, indicating cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	42.00K	269.00K	300.00K	189.00K	270.00K
Gross Profit	-1.42M	-1.67M	-1.01M	-686.00K	-888.00K
EBITDA	-71.41M	-62.48M	-27.41M	-23.42M	-19.60M
Net Income	-60.86M	-53.76M	-38.15M	1.07M	-6.56M
Balance Sheet
Total Assets	35.88M	48.45M	6.83M	8.70M	150.42M
Cash, Cash Equivalents and Short-Term Investments	8.20M	20.59M	1.38M	5.55M	501.24K
Total Debt	17.78M	16.27M	39.95M	9.80M	0.00
Total Liabilities	27.21M	28.54M	48.94M	104.57M	11.22M
Stockholders Equity	8.67M	19.91M	-42.11M	-95.88M	139.20M
Cash Flow
Free Cash Flow	-20.78M	-16.36M	-25.99M	-987.19K	-2.34M
Operating Cash Flow	-27.51M	-15.99M	-25.65M	-485.19K	-19.31M
Investing Cash Flow	-954.00K	-1.65M	-340.00K	-500.00K	-1.27M
Financing Cash Flow	990.00K	15.63M	21.88M	75.00K	151.07M

Adagio Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Negative. The current price of 0.86 is below the 20-day moving average (MA) of 1.24, below the 50-day MA of 1.60, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 24.61 is Positive, neither overbought nor oversold. The STOCH value of 5.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADGM.

Adagio Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CODX	45 Neutral	$24.42M	-0.35	-63.40%	―	-91.14%	9.47%
VVOS	44 Neutral	$17.71M	-1.26	-262.03%	―	2.65%	70.21%
PAVM	40 Underperform	$10.04M	0.32	―	―	-73.36%	―
COCH	40 Underperform	$20.88M	-0.54	―	―	-26.49%	-91.23%
ADGM	37 Underperform	$16.00M	-0.21	―	―	15.00%	71.57%
IINN	35 Underperform	$24.72M	-2.24	―	―	―	―

Adagio Medical Holdings Corporate Events

Adagio Medical’s Cryoablation Study: A Potential Game-Changer for Cardiac Treatment

Adagio Medical Holdings, Inc. is conducting a clinical study titled ‘Cryoablation for Monomorphic Ventricular Tachycardia IDE Study: EFS and Pivotal.’ The study aims to assess the safety and effectiveness of the Adagio VT Cryoablation System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT), a significant cardiac condition. This research is crucial as it could offer a new treatment avenue for patients suffering from SMVT.

Adagio Medical Sets Date for 2025 Annual Meeting

On October 23, 2025, Adagio Medical Holdings, Inc. announced the date for its 2025 Annual Meeting of Stockholders, set for December 15, 2025. The company did not hold a 2024 Annual Meeting, prompting this announcement to inform stockholders about the upcoming meeting and the deadlines for submitting proposals and nominations. Stockholders must submit their proposals or nominations by November 3, 2025, to be considered for inclusion in the meeting’s proxy materials.

The most recent analyst rating on (ADGM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Secures $19M for Cryoablation Tech

On October 20, 2025, Adagio Medical Holdings announced the closing of a $19 million private placement, aimed at advancing its proprietary Ultra-Low Temperature Cryoablation technologies for ventricular tachycardia. The funds will support FDA submission activities, enhance clinical experience, and expand manufacturing capabilities, positioning Adagio to improve treatment outcomes for VT patients and strengthen its market presence.

The most recent analyst rating on (ADGM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Raises $19M in Private Placement

On October 14, 2025, Adagio Medical Holdings entered into a Securities Purchase Agreement with accredited investors to raise approximately $19 million upfront through a private placement of common stock and warrants, with potential additional proceeds of up to $31 million upon full exercise of the warrants. The funds will be used for working capital and advancing clinical and product development activities, potentially strengthening Adagio’s market position in cardiac arrhythmia treatment technologies.

The most recent analyst rating on (ADGM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Reports Promising Results from FULCRUM-VT Study

On October 10, 2025, Adagio Medical Holdings announced preliminary acute safety and efficacy results from its FULCRUM-VT Study, which evaluates the company’s Ultralow Temperature Cryoablation (ULTC) technology for treating Sustained Monomorphic Ventricular Tachycardia (SMVT). The study, presented at the 20th Annual International Symposium on Ventricular Arrhythmias, showed a 97.4% acute clinical success rate with a favorable safety profile, highlighting the potential of ULTC technology to transform VT treatment. The study involved 207 patients across 19 sites in the U.S. and Canada, with results indicating the system’s promise for a broad patient population, including those with ischemic and non-ischemic cardiomyopathy. The company plans to share further results at the Heart Rhythm 2026 conference, aiming for FDA premarket approval.

The most recent analyst rating on (ADGM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Completes Enrollment for FULCRUM-VT Study

On October 1, 2025, Adagio Medical Holdings announced the completion of enrollment for its FULCRUM-VT Pivotal FDA IDE study, evaluating the vCLAS™ Cryoablation System for monomorphic ventricular tachycardia. The study, which enrolled 208 patients across 20 centers in the U.S. and Canada, aims to support a pre-market approval application for the system. The vCLAS System, granted Breakthrough Device Designation by the FDA, is expected to address the needs of patients with drug-refractory ventricular tachycardia, with the PMA process anticipated to complete by the end of 2026.

The most recent analyst rating on (ADGM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Holdings Appoints New CFO Deborah Kaster

On September 5, 2025, Adagio Medical Holdings appointed Deborah Kaster as Chief Financial Officer, expanding her role from Chief Business Officer. Kaster, who joined Adagio in March 2025, brings over 25 years of financial leadership experience and will oversee both business and financial operations. This strategic move aims to align Adagio’s financial and strategic priorities, enhancing its growth potential in the medical device industry.

The most recent analyst rating on (ADGM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Reports Q2 Financial Results Progress

On August 13, 2025, Adagio Medical Holdings announced its second quarter financial results, highlighting significant progress in its clinical studies and operational efficiency. The company reported a reduction in cash burn due to prioritization initiatives and continued strong enrollment in the FULCRUM-VT study, which is crucial for its market positioning in the treatment of ventricular tachycardia. Financially, Adagio reduced its net loss compared to the previous year, reflecting improved cost management and strategic focus.